TrumpRx Falls Short: Drug Discount Site a Boutique

When President Donald Trump launched TrumpRx in February 2026, he called it “the biggest thing to happen in healthcare in many, many decades” — a government website that would deliver the world’s lowest prescription drug prices to Americans. Nearly six months later, an NPR investigation has found the program has fallen significantly short of those ambitions, offering just 92 brand-name drugs — fewer than 12% of the more than 800 brand-name medications made by participating pharmaceutical companies. Critics describe the result as a “boutique” rather than the “supermarket” for cheap drugs that was promised.

The Gap Between Promise and Reality

TrumpRx launched on February 5 with 43 drugs from five manufacturers. As of mid-July, it has expanded to 92 brand-name drugs from 15 of the 17 companies that announced deals with the administration. But major blockbuster medications remain absent. Pfizer’s Eliquis, a widely prescribed blood thinner, and Ibrance, a breast cancer treatment, are not on the platform. Neither is Paxlovid, Pfizer’s COVID-19 antiviral.

Gilead and Regeneron — two companies that announced deals with the administration — still have zero drugs on TrumpRx. They have told NPR they plan to add one drug each (Epclusa for hepatitis C and Praluent for high cholesterol), but no timeline has been provided.

“The key takeaway is that most of these companies are doing this for a small number of products and in a limited setting,” said Dr. Ben Rome, a health policy researcher and physician at Brigham and Women’s Hospital. “They’re not engaging to do this on a large scale.”

Who Actually Benefits?

The program’s structural design limits its impact. TrumpRx functions as a coupon platform for cash-paying consumers — those who are uninsured or choose not to use their insurance. But approximately 66% of Americans under 65 have private insurance, and for most of them, using their coverage may be cheaper than TrumpRx discounts. A KFF analysis found that for many insured patients, insurance copays are lower than TrumpRx self-pay prices, and using insurance counts toward deductibles and out-of-pocket maximums.

Health economist Rena Conti of Boston University noted that drug companies are selectively offering discounts. “The companies are offering deals on the products that they choose, not the universe of products that they offer,” she said. “That consequently sounds good and may help a small share of people who are purchasing these products at a cash price but are not helping all the consumers of their products.”

Generic Competition Undercuts ‘Presidential Deals’

Many of the brand-name drugs featured as “presidential deals” on TrumpRx have cheaper generic alternatives. For example, Pfizer’s Xeljanz, a rheumatoid arthritis treatment, costs $1,518 on TrumpRx (a 53% discount off the brand price), but the generic tofacitinib is available for about $30 on Cost Plus Drugs. Similarly, Pristiq, an antidepressant, is listed at $200.10 on TrumpRx, while its generic costs $20 to $30 with a GoodRx coupon.

In May, TrumpRx added hundreds of generic drugs through partnerships with Cost Plus Drugs, Amazon Pharmacy, and GoodRx, effectively splitting the site into “presidential deals” (brand-name) and “standard prices” (generics). But critics note the site does not prominently warn consumers when a cheaper generic exists for a brand-name “deal.”

Price Hikes Despite Agreements

All 16 companies that announced deals with the Trump administration raised list prices on other products in January 2026, with a median increase of 4%, according to an analysis by 46brooklyn, a drug price research firm. Pfizer raised prices on 72 products, including a 15% increase on its COVID-19 vaccine. Antonio Ciaccia, CEO of 46brooklyn, told NPR: “The real truth serum is what’s happening in the marketplace after those deals occur.”

TrumpRx’s website claims over $400 million in savings for Americans, but this statistic has not been updated in over a month and is difficult to verify independently.

International Comparisons

A March 2026 analysis by The New York Times found that while TrumpRx reduced some prices, it did not generally offer Americans lower drug prices than other wealthy countries. In some cases, TrumpRx prices were twice as high as those in comparable nations.

A Politically Polarizing Program

The program’s branding has proven politically divisive. A YouGov survey found 57% approval when the website was described without naming TrumpRx, but approval dropped to 41% when the name was mentioned. Among Democrats, approval fell from 45% to 13% when the Trump branding was attached.

What’s Next?

Despite its limitations, TrumpRx has provided genuine savings for some patients — particularly those seeking GLP-1 weight loss drugs and fertility medications that are often not covered by insurance. The program also represents a significant policy shift: the administration’s willingness to use tariff authority to compel industry participation.

As Forbes analysis concluded, TrumpRx is “best seen not as a finished reform but as an opening move in a longer negotiation” between the administration and the pharmaceutical industry. Whether the program expands to include more major drugs — and whether proposed Medicare models like GLOBE and GUARD proceed — will determine if 2026 marks a genuine turning point in American drug pricing or simply another chapter in a long-running debate.”